Introduction
All cells in the body are descendants of a single cell, the fertilized egg. The development of a complete embryo requires multiplication of the fertilized egg and differentiation of the progeny to all the different cell types of the body. These functions are carried out by the inner mass cells of the preimplantation blastocyst. When cultured in vitro in the presence of differentiation inhibiting signals, these inner mass cells can be propagated for many cell generations as cell lines called embryonic stem (ES) cells (Evans and Kaufman, 1981) . ES cell lines can also be derived from single blastomeres of an 8-cell embryo (Chung et al., 2006) and can undergo differentiation to a variety of cell types in vitro, depending on the stimuli provided (Rippon and Bishop, 2004) . ES cells are thus characterized by their ability to self renew and their multipotent differentiation. In adult life, different tissues also contain somatic stem cells, which will be referred to as adult stem cells, that reside in specific niches and can self-renew and differentiate to the various cell types of these tissues (Fuchs and Segre, 2000; Calvi et al., 2003; Zhang et al., 2003; Li and Xie, 2005 ). We will review recent studies that show that the differentiation potential of adult stem cells is broader than originally anticipated. The plasticity of differentiation in ES and adult stem cells, which is epigenetically controlled, is the basis for their clinical use in regenerating damaged tissues.
Genetic and/or epigenetic changes can affect the normal processes of multiplication and differentiation and lead to development of cancer. Cancer is also maintained by self-renewing stem cells, but do cancer stem cells show plasticity of differentiation? We will show that, like embryonic and adult normal stem cells, cancer stem cells have an epigenetically controlled plasticity of differentiation, which is associated with transcription accessibility for genes that are preferentially expressed in different normal tissues. We will also discuss the contribution of this broad transcription accessibility to the behavior of cancer cells.
Epigenetic control of gene expression
Almost all cells in the body have the same genome, yet they show a great diversity of cell types with different functions. This diversity is determined by activating or silencing expression of various genes by epigenetic changes that reprogram the genome function during development (Reik et al., 2001; Surani, 2001 ). Gene silencing is mainly achieved by methylation of cytosine residues in DNA at CpG dinucleotides in gene promoters and is carried out by specific DNA methyltransferases (Freitag and Selker, 2005) . This methylation can prevent binding of certain transcription factors to these CpG islands (Weih et al., 1991; Campanero et al., 2000) and can also induce preferential association with deacetylated histones (Eden et al., 1998) . This association is mediated by methyl cytosine-binding proteins of the MBD and MeCP families that recruit transcription-repressing complexes containing histone deacetylases (Bird and Wolffe, 1999) and histone methylases (Bannister et al., 2001; Lachner et al., 2001) . Demethylation of DNA and/or histone acetylation can induce structural changes in chromatin that activate gene expression during differentiation (Paroush et al., 1990; Lubbert et al., 1996; Avni and Rao, 2000; Miyata et al., 2001; Muller and Leutz, 2001 ).
Epigenetic control of differentiation and transcription accessibility for genes of different tissues in normal embryonic stem cells Epigenetic changes involving DNA methylation and subsequent silencing of certain genes are required for induction of differentiation of ES cells. This was shown in experiments with ES cells deficient either in the DNA methyltransferases Dnmt1, both Dnmt3a and Dnmt3b, or the CpG island-binding protein CGBP that binds to non-methylated DNA. These cells showed severe DNA hypomethylation and a complete differentiation block (Jackson et al., 2004; Carlone et al., 2005) . The behavior of ES cells in vitro is like the in vivo regulation of gene expression during early embryonic development, which requires epigenetic reprogramming (Reik et al., 2001; Surani, 2001) . Initially almost all the methyl groups in the DNA inherited from the male and female gametes in the fertilized egg are erased (Monk et al., 1987) , followed by re-establishment of DNA methylation during implantation (Kafri et al., 1992) . However, CpG islands that control gene expression remain unmethylated at this stage, and their de novo methylation and gene silencing occur postimplantation. This mechanism is responsible for silencing the self-renewal gene Oct4 (Gidekel and Bergman, 2002) and the genes on the inactive X chromosome in females in postimplantation embryos (Lock et al., 1987) .
It has been shown that the number of genes that are highly expressed in undifferentiated ES cells is much higher than in adult tissues (Ramalho-Santos et al., 2002; Golan-Mashiach et al., 2005) . This includes genes expressed in differentiated tissues (Bhattacharya et al., 2004; Golan-Mashiach et al., 2005) , and when ES cells differentiate to a particular cell lineage many genes are downregulated (Golan-Mashiach et al., 2005) . These results indicate that the transcription accessibility for many genes specific to various tissues is a major factor in determining the plasticity of differentiation in ES cells. This property is presumably due to the unmethylated state of many CpG islands in ES cells, which renders them accessible for transcription. The ability of embryonic cells to rapidly demethylate transfected DNA whose CpG islands were fully methylated in vitro (Frank et al., 1991) , lends further support to the ability of ES cells to keep CpG islands of many genes in an unmethylated state that facilitates their expression. The hyperdynamic loose binding of chromatin-associated proteins in ES cells may also contribute to the transcription accessibility and multipotency of these cells (Meshorer et al., 2006) .
Epigenetic control of differentiation and transcription accessibility for genes of different tissues in normal adult stem cells Normal adult tissues contain stem cells that are responsible for regenerating these tissues (Spangrude et al., 1991; Nagano et al., 1998; Gage, 2000; Temple, 2001; Marshman et al., 2002; Alonso and Fuchs, 2003; Kubota et al., 2004; Collins et al., 2005; Shackelton et al., 2006) . Adult stem cells reside in specific niches within different issues (Fuchs and Segre, 2000; Calvi et al., 2003; Zhang et al., 2003; Li and Xie, 2005) . Niches can be reproduced in vitro by using different types of cells as feeder layers. Feeder layers were used for the in vitro cloning of hematopoietic stem cells (Ginsburg and Sachs, 1963; Sachs, 1964; Pluznik and Sachs, 1965) and it was shown that these feeder layers produce and can secrete the cytokines required for cell viability, growth and differentiation Sachs, 1965, 1966; Ichikawa et al., 1966; Sachs, 1995 Sachs, , 1996 . It was assumed that the differentiation potential of adult stem cells is strictly tissue-specific. However, recent studies have shown that adult stem cells obtained from different tissues have a much broader plasticity of differentiation than originally anticipated (Fuchs and Segre, 2000; Lotem and Sachs, 2002a; Herzog et al., 2003; MartinRendon and Watt, 2003) . It has also been shown that the multipotential differentiation of adult stem cells can occur without cell fusion (Harris et al., 2004; Jang et al., 2004; Wurmser et al., 2004) .
Under certain conditions, especially after tissue injury, adult hematopoietic stem cells can differentiate to cells of neural lineage (Eglitis and Mezey, 1997; Sigurjonsson et al., 2005) , liver (Alison et al., 2000; Lagasse et al., 2000; Theise et al., 2000; Krause et al., 2001; Jang et al., 2004) , muscle (Camargo et al., 2003; Corbel et al., 2003) , skin (Krause et al., 2001 ) and endothelium (Orlic et al., 2001; Bailey et al., 2004) and can thus contribute to regeneration of these tissues when they are damaged. Mesenchymal stem cells in the bone marrow can differentiate to muscle (Ferrari et al., 1998; Dezawa et al., 2005) , neural lineage cells (Kopen et al., 1999; Dezawa et al., 2004) and to various other cell types (Jiang et al., 2002) . Another distinct population of bone marrow-derived stem cells can differentiate to cells of various lineages including muscle, endothelial, epithelial and neural cells (Yoon et al., 2005) . Other adult stem cells that can be induced to differentiate to a different cell type, include skeletal muscle stem cells to blood cells (Jackson et al., 1999; Cao et al., 2003) and neural cells (Romero-Ramos et al., 2002) ; cardiac muscle stem cells to endothelial cells (Mohri et al., 2006) ; neural stem cells to blood and endothelial cells (Bjornson et al., 1999; Wurmser et al., 2004) ; hair follicle stem cells to neural lineage cells (Amoh et al., 2005a, b) ; and testis-derived stem cells to a wide variety of cell types (KanatsuShinohara et al., 2004; Guan et al., 2006) . The use of adult stem cells has thus considerable therapeutic potential for the regeneration of damaged tissues. Adult stem cells have the additional advantage that they can be used as autologous transplants whereas transplants of embryonic stem cells are generally allogeneic transplants.
The differentiation multipotency of adult stem cells indicates that their genome can be epigenetically reprogrammed under the right conditions. An example of such reprogramming came from nuclear transfer experiments in sheep, in which the nucleus of an adult diploid somatic cell transferred to an enucleated oocyte was reprogrammed to produce an adult animal (Wilmut et al., 1997) . Transfer of mammalian cell nuclei into Xenopus oocytes has shown that DNA demethylation was necessary for reprogramming gene expression in the transferred somatic cell nuclei, including expression of the self-renewal gene Oct4 Gurdon, 2004, 2005) . Even without nuclear transfer, induction of cell differentiation and cell fate determination in normal adult stem cells are controlled by epigenetic changes in DNA and chromatin (Ariel et al., 1994; Ansel et al., 2003; Tagoh et al., 2004a, b; Fan et al., 2005; Goldmit et al., 2005; Roloff and Nuber, 2005; Xi and Xie, 2005) . Compounds that inhibit DNA methylation or histone deacetylation can induce cell differentiation in vitro Roloff and Nuber, 2005) and in vivo (Schmittwolf et al., 2005) . The finding that differentiation-associated epigenetic changes are reversible (Tagoh et al., 2004b) , can explain the ability to change already established cell fate lineage decisions (Yamaguchi et al., 1991; Katagiri et al., 1994; Xie et al., 2004; Baba et al., 2005; Hsu et al., 2006) .
The results described above raised the question whether as in ES cells, the differentiation plasticity of adult stem cells is also associated with transcription accessibility for genes of different tissues. Results with hematopoietic stem cells and CD34 positive hematopoietic progenitors have shown, that these cells express genes that are expressed in neural and various other normal nonhematopoietic tissues (Luce and Burrows, 1999; Akashi et al., 2003; Goolsby et al., 2003; Georgantas et al., 2004; Steidl et al., 2004) . Skeletal muscle stem cells express neural stem cell genes and adult bone marrow-derived mesenchymal stem cells express different mesenchymal genes as well as genes of various other lineages including neuronal, testis, liver, lung, hematopoietic and endothelial tissues (Woodbury et al., 2002; Seshi et al., 2003) . The differentiation plasticity of adult stem cells, like in ES cells, is thus associated with transcription accessibility for genes that are normally preferentially expressed in different tissues (Table 1) . 
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Epigenetic control of cancer development Development of cancer involves both genetic changes in the DNA (Klein, 1981; Rowley, 1998) as well as epigenetic changes in DNA and chromatin that affect growth and differentiation (Cairns, 2001; Robertson, 2001; Rountree et al., 2001; Wolffe, 2001; Herman and Baylin, 2003; Feinberg and Tycko, 2004; Lund and van Lohuizen, 2004; Feinberg et al., 2006) . The importance of epigenetic changes in cancer development was shown in experiments in which reducing the level of DNA methylation to 10% of normal levels by introducing a hypomorphic allele of the DNA methyltransferase gene Dnmt1 was sufficient to induce cancer development in mice , presumably due to induction of chromosome instability . Studies on human colorectal cancers have shown that 30-40% of patients show aberrant loss of imprinting (LOI) of the IGF2 gene due to loss of DNA methylation in the maternal IGF2 allele, both in the tumor and in the tumor's neighboring normal mucosa cells (Cui et al., 1998 (Cui et al., , 2003 . About 10% of the normal human population show LOI of IGF2 in their peripheral blood cells and this population has a fivefold higher risk of developing colorectal cancer (Cui et al., 2003) . Mice with LOI of Igf2 expressed higher levels of Igf2, their colonic mucosa showed aberrant differentiation, and the mice were more prone to develop colorectal cancer (Kaneda and Feinberg, 2005; Sakatani et al., 2005) . These results indicate that impairment of the normal parental imprinting of a gene such as IGF2 can lead to elevated levels of IGF2, which affects growth and differentiation and promotes cancer development. Several studies have shown that the epigenetic changes that occur in cancer include not only promoter CpG island hypermethylation and silencing of tumor suppressor genes (Herman and Baylin, 2003) , but also promoter CpG island hypomethylation (Feinberg and Vogelstein, 1983; Kaneda et al., 2004) . Such promoter hypomethylations in different cancers were associated with upregulated expression of tumor promoting genes such as BCL2 (Hanada et al., 1993) , MDR1 (Nakayama et al., 1998) , HOX11 (Watt et al., 2000) , MYC, c-Ha-RAS, c-FOS and ALPHA FETOPROTEIN (Fang and Xiao, 2001) , MASPIN (Ogasawara et al., 2004) , MEL1S (Yoshida et al., 2004) , EGR1 that upregulates expression of heparanase (Ogishima et al., 2005) , SYNUCLEIN GAMMA (Gupta et al., 2003; Liu et al., 2005) and some other genes (Sato et al., 2003) . Exogenously added estrogen or tamoxifen can induce promoter hypomethylation of PAX2 , and treatment with chemotherapeutic compounds can induce Histone-H3 acetylation and Histone-H3 lysine-4 methylation at the MDR1 promoter (Baker et al., 2005) that result in upregulation of these tumor promoting genes. In addition to genetic changes that cause cancer, aberrant silencing of tumor suppressor genes and aberrant activation of tumor promoting genes through epigenetic changes can thus also lead to cancer development. Even monozygotic twins that have the same genetic constitution undergo an age-dependent epigenetic drift, resulting in differences in Histone acetylation and DNA methylation, both in repeat DNA and in single genes, which lead to altered gene expression (Fraga et al., 2005) . Such age-dependent epigenetic changes induced by various environmental factors, may lead to altered phenotypes including higher susceptibility to cancer.
Epigenetic control of differentiation in cancer stem cells
Studies on the chromosomes (Levan and Hauschka, 1953; Makino and Kano, 1953; Sachs and Gallily, 1955; Hayashi et al., 1974) and other properties of cancer cells (Kleinsmith and Pierce, 1964; Bonnet and Dick, 1997; Kondo et al., 2004) have shown that cancers also have self-renewing stem cells. It has recently been emphasized that cancer therapy should include the targeting of cancer stem cells (Singh et al., 2003; Valk-Lingbeek et al., 2004; Behbod and Rosen, 2005; Bjerkvig et al., 2005; Bonnet, 2005) . Although cancer cells can be derived from normal self-renewing stem cells, more differentiated normal cells can also give rise to tumors (Cozzio et al., 2003; Castor et al., 2005) . Experiments with mature brain astrocytes have shown that combined loss of the tumor suppressor genes p16
Ink4 and p19
Arf and constitutive activation of the EGF receptor caused a loss of differentiation. These cells regained neural stem cell properties and formed glioblastomas when injected into mouse brains (Bachoo et al., 2002) . Cancer stem cells can thus be derived both from normal stem cells and from more differentiated cells that are reprogrammed to express the properties of stem cells. Although the genetic and epigenetic changes in cancer are associated with aberrant growth and differentiation, cancer cells have not always lost their differentiation potential and can be induced to differentiate to mature cells. Some cancers can be induced to differentiate by cytokines that regulate the differentiation of normal cells, whereas other cancers can differentiate in response to a variety of compounds including retinoic acid, dexamethasone, cytosine arabinoside and others (Sachs, 1978 (Sachs, , 1987a (Sachs, , b, 1995 (Sachs, , 1996 Lotem and Sachs, 2002a, b) . The differentiation of cancer cells is associated with epigenetic reprogramming of their DNA and/or chromatin (Razin et al., 1984; Cairns, 2001; Hong et al., 2001; Zhu et al., 2001; Di Croce et al., 2002) . In some cases cancer cell differentiation can be induced by inhibitors of DNA methyltransferases (Dore et al., 1998) and/or histone deacetylases (Cameron et al., 1999; Wang et al., 1999; Marks et al., 2001; Munster et al., 2001) . The epigenetic suppression of malignancy by inducing differentiation can bypass the genetic abnormalities in cancer, and this epigenetic reprogramming is the basis for differentiation therapy of cancer (Sachs, 1978; Altucci and Gronemeyer, 2001 
Plasticity of differentiation in cancer stem cells and transcription accessibility for genes of different tissues
The plasticity of differentiation in normal ES and adult stem cells raises the question whether cancer stem cells also have a plasticity of differentiation. Teratocaricnomas arise from defective germ cells in testis, and embryonal carcinoma (EC) cells derived from such teratocarcinomas can form normally appearing embryoid bodies in vitro and differentiate to cells of all three germ layers like normal ES cells (Kleinsmith and Pierce, 1964; Martin and Evans, 1975) . EC cell lines can also be induced to differentiate to neurons, skeletal muscle and cardiac muscle when cultured in the presence of different inducers (Bain et al., 1994; Skerjanc, 1999; van der Heyden and Defize, 2003) . Cancer stem cells from leukemia (Sachs, 1978 (Sachs, , 1987a (Sachs, , b, 1995 (Sachs, , 1996 Sachs, 1978, 1979; Griesinger et al., 1989; Nakamura et al., 1991) , neuroblastoma (Ciccarone et al., 1989) , colon carcinoma (Velcich et al., 1995) and hepatocellular carcinoma (Shachaf et al., 2004) can differentiate to different cell types that are normally found in normal blood, brain, colon and liver, respectively. But does the differentiation plasticity of cancer stem cells extend beyond the lineage from which they were derived? In analogy with the normal ES and adult stem cells, such broad plasticity in cancer stem cells would presumably be associated with transcriptional accessibility for genes of tissues other than those from which the cancers originated.
Cancer cell lines have a high percentage of cycling cells and a high cloning efficiency, and they can be regarded as having a high frequency of cancer stem cells. DNA microarray data and cluster analysis of expressed genes from these cancer stem cells and from different normal tissues were used to search for genes that are highly expressed in cancer stem cells, and whose preferential expression in normal tissues is found in tissues other than those from which the cancers originated (Lotem et al., 2004 (Lotem et al., , 2005 . Using a mouse myeloid leukemia cell line, it was shown that the leukemic cells highly expressed genes that are normally preferentially expressed in various mouse nonhematopoietic tissues. This analysis showed that in addition to genes that are normally preferentially expressed in hematopoietic tissues, the myeloid leukemia cell line also highly expressed more than 120 genes that are normally preferentially expressed in nonhematopoietic tissues such as neuronal, muscle, liver and testis (Lotem et al., 2004) (Table 1) . Activation of wild-type p53, or treatment of these leukemic cells with the cytokine IL-6 or the calcium mobilizing compound thapsigargin, induced other genes that were preferentially expressed in these normal nonhematopoietic tissues (Lotem et al., 2004) . Gene expression data from normal human tissues, six human leukemia and lymphoma cell lines and a colon carcinoma cell line (Su et al., 2004) , has identified genes that were highly expressed in the human cancer cell lines but not in their normal counterparts (Lotem et al., 2005) . These genes are thus overexpressed in these cancer cell lines. Analysis of the expression profile of these genes in normal tissues showed that many of these genes were preferentially expressed in different normal tissues, including neuronal, testis, liver, thyroid, adrenal, kidney, pancreas, lung and placenta (Lotem et al., 2005) (Table 1) . These results with cancer cell lines raised the question whether primary cancer cells also have transcriptional accessibility for genes of other tissues? Using gene expression data from leukemic cells obtained from 267 lymphoid and myeloid leukemia pediatric patients (Ross et al., 2003 (Ross et al., , 2004 , it was shown that these primary leukemic cells highly express different genes that are normally preferentially expressed in various nonhematopoietic normal tissues including neuronal, liver, kidney, adrenal, testis and placenta (Lotem et al., 2005) (Table 1) .
Different types of cancers, both solid tumors and leukemias, express certain genes that are normally expressed only in germ line cells and are thus called cancer/testis (CT) genes (Adams et al., 2002; Scanlan et al., 2004; Guinn et al., 2005; Simpson et al., 2005) . Analysis of global gene expression in different types of human cancers compared to the normal tissue from which the cancers originated, has identified many genes that are overexpressed in the cancers (Okutsu et al., 2002; Ma et al., 2003; Sotiriou et al., 2004; Jarzab et al., 2005; Yu et al., 2005; Lee et al., 2006b ). The expression profile of genes in different normal human tissues (Lotem et al., 2005) was used to analyse the expression of overexpressed genes in tissues other than the tissue from which the cancer originated (Table 2) . For example, EZH2 is overexpressed in prostate cancer (Varambally et al., 2002) whereas it normally shows preferential expression in hematopoietic tissue and testis. GHRH that encodes growth hormone releasing hormone is overexpressed in various types of cancer including non-Hodgkin lymphoma (Havt et al., 2005) whereas it normally shows preferential expression in the pituitary and to a lesser extent in kidney and liver. DCD is overexpressed in invasive breast carcinoma (Porter et al., 2003) , L1CAM is overexpressed in colon cancer (Gavert et al., 2005) and in the colon cancer cell line SW480 (Lotem et al., 2005) , SYNUCLEIN GAMMA is overexpressed in many cancers due to hypomethylation of its promoter (Gupta et al., 2003; Liu et al., 2005) and TRKB is overexpressed in many cancers (Geiger and Peeper, 2005) , whereas they normally show preferential expression in brain. Of the genes that are overexpressed in thyroid cancer (Jarzab et al., 2005) , MAP17 is normally preferentially expressed in kidney and LAMB3 and SLC34A2 are normally preferentially expressed in lung. Of the genes expressed in leukemia but not in normal hematopoietic tissues (Andersson et al., 2005) , GPRC5B, COBL, PLXNB1, TUSC3 and KIAA1644 are normally preferentially expressed in neuronal tissues (Table 2) .
These results and those shown in Tables 1 and 2 indicate that both cancer stem cells in cell lines and cancer cells from primary tumors show transcriptional accessibility for genes that are normally expressed in tissues other than the cancer's origin. This suggests that under the right conditions the cancer cells may have a Differentiation plasticity in normal and cancer stem cells J Lotem and L Sachs much broader plasticity of differentiation than previously anticipated. This possibility is supported by the finding that transfer of nuclei from medulloblastoma (Li et al., 2003) or from leukemia, lymphoma, breast carcinoma and melanoma cells (Hochedlinger et al., 2004) into enucleated mouse oocytes, showed in vitro development of apparently normal preimplantation embryos up to the blastocyst stage. The medulloblastoma-derived blastocysts could even develop to postimplantation embryos after transfer to pseudo-pregnant females, although no embryos survived beyond day E8.5 of gestation (Li et al., 2003) .
Role of overexpression of genes of different normal tissues in regulating cancer cell behavior
The transcription accessibility in cancer cells for genes of normal tissues other than the cancer's origin raises the question whether their overexpression affects cancer cell behavior. Regarding the CT genes, expression of MAGEA1, MAGEA2 and MAGEA3 increased cancer cell resistance to tumor necrosis factor and expression of MAGEA2 or MAGEA6 increased resistance to chemotherapeutic compounds (Simpson et al., 2005) . Piwi2, another testis gene (Sasaki et al., 2003) that is essential for normal spermatogenesis (Deng and Lin, 2002) , plays an important role in the self-renewal of spermatogenic stem cells (Cox et al., 1998) . Piwi2 is expressed in many tumors, thus qualifying as a CT gene, and this gene can upregulate expression of the antiapoptotic protein BclxL through activation of STAT3, thus inhibiting apoptosis and promoting growth of the tumor cells (Lee et al., 2006a) . Another CT protein, BORIS, promotes cell proliferation in cancer cells (Klenova et al., 2002) . BORIS can regulate organization of epigenetically controlled chromatin by interacting and inhibiting the activity of the transcription silencer CTCF, and thus may contribute epigenetically to the abnormal expression of silenced genes in cancer (Klenova et al., 2002) .
Not only CT genes can contribute to cancer development. Many of the genes detected as overexpressed in human cancers and preferentially expressed in normal tissues other than the tumor's origin, can contribute to cancer development by promoting cancer cell viability, growth and metastasis ( 
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For example, the colon carcinoma cell line SW480 overexpressed the apoptosis inhibitors SERPINA1 and BIRC5/SURVIVIN and the genes RUNX1, LMO2 and TCF3/E2A that are involved in cancer-associated translocations, which are normally preferentially expressed in hematopoietic tissues (Lotem et al., 2005) . EZH2 is a Polycomb family gene that is involved in regulating self-renewal in normal adult stem cells by virtue of its participation in epigenetic chromatin modifying complexes (Lund and van Lohuizen, 2004) and this property can explain how its overexpression contributes to the aggressiveness of prostate cancer (Varambally et al., 2002) . TRKB, which encodes a neurotrophin receptor and is overexpressed in many types of cancer, functions as an apoptosis inhibitor and is involved in metastasis (Geiger and Peeper, 2005) . SYNUCLEIN GAMMA, which is overexpressed in many cancers due to hypomethylation of its promoter (Gupta et al., 2003; Liu et al., 2005) , functions as an apoptosis inhibitor (Pan et al., 2002) , a proliferation promoter (Liu et al., 2000) and a promoter of chromosomal instability (Inaba et al., 2005) . DCD, which is overexpressed in invasive breast cancer, is a survival factor (Porter et al., 2003) and L1CAM, which is a target of the b-catenin pathway that is activated in various cancers including colon cancer (Boon et al., 2004; Gavert et al., 2005) , contributes to the metastatic potential of colon cancer (Gavert et al., 2005) . These results support the suggestion that the ability to overexpress genes that are normally preferentially expressed in tissues other than the cancer's origin, is a general property of cancer cells that plays an important role in determining the behavior of the cancers, including their metastatic potential (Lotem et al., 2005) . The gene expression profiles of pediatric leukemia patients has shown that lymphoid leukemias overexpressed three times as many nonhematopoietic genes, including genes preferentially expressed in neuronal tissues and testis, compared to the myeloid leukemias (Lotem et al., 2005) . This is associated with a higher incidence of leukemia involvement in the central nervous system in ALL compared to AML pediatric patients (Pui et al., 1998; Dusenbery et al., 2003) . The further search for such associations in different types of cancer would be a useful addition to cancer diagnosis and for planning cancer therapy.
